The Healthtech Times is a weekly newsletter covering healthtech news from Canada and around the globe. Subscribe to H|T using the form at the bottom of this page to ensure you don’t miss out on the most important healthtech news every week!
“After a brain injury of any description … there is always the question that is asked by the physician or healthcare provider, ‘Can he or she hear me? Do they understand what I’m saying?’” Connolly told BetaKit in an interview. “And they still reply, ‘We don’t know.’”
Zymeworks strikes $1.8-billion licensing deal labelled ‘bad’ for shareholders by hostile suitor (THE GLOBE AND MAIL)
"This agreement creates significant value for Zymeworks and its stockholders,” chief executive officer Kenneth Galbraith said during a conference call to discuss the deal.
But the deal was criticized by one of Zymeworks’ largest shareholders, Dubai-based hedge fund All Blue Falcons FZE, which offered this year to buy the company for US$10.50 a share, or US$773-million, in a hostile, non-binding bid that the company has rebuffed.
Similar to last year, SAAS NORTH’s main stage will be renamed the BetaKit Keynote Stage for the entirety of the two-day conference, featuring content co-programmed and moderated by BetaKit.
Feds taking a deeper look at CVS-Signify deal (FIERCE HEALTHCARE)
In a filing with the Securities and Exchange Commission, CVS Health said the Department of Justice (DOJ) sent the companies a second request for information on the merger on Oct. 19. The second request allows the agency 30 extra days to probe the merger
"CVS Health and Signify Health have been working cooperatively with the DOJ and will continue to do so," CVS said in the filing.
Eligible companies can also access additional investment of up to $400,000 from the Ontario Brain Institute, commercialization and funding support from Ontario Bioscience Innovation Organization, and business financing from Clearco.
The appointment to minister of technology and innovation will likely come as no surprise as Glubish (formerly minister of Service Alberta) has a history with the innovation sector and has been vocal about his interest in tech.
Tech firm listed as having received ArriveCan contract never worked on the app, CEO says (THE GLOBE AND MAIL)
Craig McLellan said he was surprised to read in The Globe and Mail that his company, ThinkOn Inc., was listed as the sixth-ranked company in terms of federal outsourcing contracts related to developing and maintaining the ArriveCan app.
“We have received no money from the CBSA,” Mr. McLellan said in an interview.
The two lawsuits said Masimo copied Apple's technology while seeking bans on sales and imports of Apple Watches in earlier intellectual-property cases against the tech giant in California and at a U.S. trade tribunal. Apple said Masimo "carefully studied Apple's IP" during those cases and claimed a Masimo spinoff received confidential information about the Apple Watch.
The appointment to Volta’s permanent CEO comes five months after Cooper took on the interim role in May. He replaced outgoing CEO Martha Casey, who announced her departure in April to work with the International Institute for Sustainable Development.
Redesign Health lays off 67 employees in 'restructuring move' (MOBIHEALTH NEWS)
After raising $65 million in a Series C round approximately one month ago, Redesign Health, a company that builds, launches and finds funding for other healthcare startups, is laying off 67 employees, or roughly 20% of its workforce.
The board consists of Exchange Income Corporate CEO Mike Pyle, who will serve as the board’s chair, as well as Falcon Capital Corporation president Steve Kroft, Enns Brothers CEO Ray Bouchard, University of Winnipeg chancellor Barb Gamey, and Manitoba Technology Accelerator CEO Marshall Ring.
Founded in 2008, MDBilling provides a software-based medical billing solution. According to the company, its platform is used by nearly 9,000 Canadian physicians, with more than $2.3 billion in claims paid for the Ontario Health Insurance Plan (OHIP) since its inception.
Montreal’s Inversago raises $95-million led by NEA to revive failed class of weight-loss drugs (THE GLOBE AND MAIL)
Inversago Pharma Inc. drew the funding from lead investor New Enterprise Associates, one of the most established American financiers in life sciences, as well as another new investor, Amgen Ventures. It also received funding from past backers Forbion – a Dutch venture-capital company – Canadian investors Fonds de solidarité FTQ, Genesys Capital and AmorChem LP and the Juvenile Diabetes Research Foundation’s JDRF T1D venture-capital fund.
Subscribe to The Healthtech Times
Don’t forget to subscribe to The Healthtech Times using the form below to make sure it hits your email inbox every week!